USPTO Examiner ROGERS JAMES WILLIAM - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19324663MARINE ORGANISM INFUSED EFFERVESCENT TABLET FOR PRODUCING ENHANCED SUSPENSIONSSeptember 2025January 2026Allow401YesNo
188719621,4-BIS-(2-HYDROXY-BENZYL)-1,4,7-TRIAZACYCLONONANE DERIVATIVES AND SIMILAR COMPOUNDS AS LIGANDS IN IRON(III) COMPLEXES FOR USE AS MRI CONTRAST AGENTSDecember 2024June 2025Allow601NoNo
18915867HYDROXYAPATITE-ENCLOSED ZINC PHOSPHATE NANOCOMPOSITEOctober 2024December 2024Allow200YesNo
18902113POLYMER NANOPARTICLE COMPOSITIONS FOR IN VIVO EXPRESSION OF POLYPEPTIDESSeptember 2024July 2025Allow911YesNo
18669670NEAR-INFRARED (NIR) ABSORBING PHOTOSENSITIZERSMay 2024January 2026Allow2011YesNo
18643088STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOFApril 2024February 2025Allow1020YesNo
18640787CHITOSAN-HYBRIDIZED ZINC PHOSPHATE/HYDROXYAPATITE NANOSTRUCTURE-BASED DRUG DELIVERY SYSTEMApril 2024October 2024Allow610NoNo
18637431NANOPARTICLES WITH NON-COVALENTLY BOUND TARGETING MOIETIES FOR USE IN A THERAPEUTIC METHOD AND FOR NON-MEDICAL USEApril 2024August 2025Abandon1621NoNo
18625544Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use ThereofApril 2024March 2025Allow1111YesNo
18617245FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOFMarch 2024November 2024Allow800YesNo
18595720GEL MATERIAL FOR OPHTHALMIC TREATMENT USEMarch 2024June 2025Abandon1510NoNo
18588605COMPOSITIONS AND METHODS OF USE THEREOFFebruary 2024September 2025Allow1920YesNo
18392458SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTSDecember 2023July 2024Allow710NoNo
18392939REJUVENATION OF CAR T CELLDecember 2023December 2025Allow2411YesNo
18530764NOVEL, HEAVY VITAMIN B12 DERIVATIVESDecember 2023February 2025Allow1510YesNo
18529587VIRUCIDAL NANOPARTICLES AND USE THEREOF AGAINST INFLUENZA VIRUSDecember 2023May 2025Allow1811NoNo
18524929RADIOPAQUE NANOPARTICLES FOR MEDICAL IMAGINGNovember 2023March 2026Allow2740YesNo
18518499APPLICATION OF PHENYL GLUCURONIDE IN PREPARING DRUG FOR PRE-WARNING OF CANCER VIA INDUCED VOLATOLOMICSNovember 2023August 2024Allow910NoNo
18516167NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERSNovember 2023May 2025Allow1701YesNo
18503465PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOFNovember 2023February 2025Abandon1510NoNo
18498744NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALSOctober 2023October 2025Allow2411YesNo
18368695ABSORBABLE SUTURE CONTAINING HYALURONIC ACID AND MANUFACTURING METHOD THEREFORSeptember 2023May 2025Abandon2030YesNo
18233135RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOFAugust 2023August 2024Allow1210YesNo
18351291CONJUGATES ENHANCING TOTAL CELLULAR ACCUMULATIONJuly 2023April 2025Allow2130NoNo
18338832METHOD FOR CONJUGATING ANTIBODY AND PHYSIOLOGICALLY ACTIVE SUBSTANCEJune 2023February 2024Allow800NoNo
18022800NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOFJune 2023February 2026Allow3500NoNo
18202377DRESSINGS COMPRISING PLATELET LYSATEMay 2023November 2025Allow3021NoNo
18038851PEPTIDE RECEPTOR RADIONUCLIDE THERAPYMay 2023January 2026Allow3200NoNo
18317747RADIOPAQUE POLYMERSMay 2023August 2024Allow1510NoNo
18142409TOPICAL GLYCOPYRROLATE FORMULATIONSMay 2023July 2024Abandon1410NoNo
18142017Contact Lenses And Other Eye-Contacting Matrices Carrying Mitochondrially-Targeted AntioxidantsMay 2023April 2025Abandon2320YesNo
18187709METHOD FOR PREPARING CYCLODEXTRIN METAL ORGANIC FRAMEWORK (CD-MOF) STABLE IN AQUEOUS PHASEMarch 2023May 2023Allow200NoNo
18101636DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYEJanuary 2023May 2024Allow1610NoNo
18152430BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENTJanuary 2023March 2026Abandon3840YesNo
18063613SURFACE CONJUGATION TO POLY(AMINE-CO-ESTER) NANOPARTICLES FOR TARGETING TO CELLS AND TISSUESDecember 2022May 2025Abandon2940YesNo
17996420STERICALLY SHIELDED HEPTAMETHINE CYANINE DYESOctober 2022July 2025Allow3300NoNo
18045596NOVEL, HEAVY VITAMIN B12 DERIVATIVESOctober 2022September 2023Allow1110YesNo
17962297DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERYOctober 2022December 2024Abandon2611NoNo
17939528POLY (BETA-AMINO ESTERS) AND USES THEREOFSeptember 2022January 2023Allow500NoNo
17885974NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERSAugust 2022August 2023Allow1211NoNo
17879441PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERYAugust 2022March 2024Allow1920NoYes
17879430PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERYAugust 2022March 2024Allow1920NoYes
17794807NOVEL GADOLINIUM-BASED COMPOUND, PREPARATION METHOD THEREFOR, AND MRI CONTRAST AGENT CONTAINING SAMEJuly 2022May 2025Allow3400YesNo
17810591NOVEL BLOCK COPOLYMER AND MICELLE COMPOSITIONS AND METHODS OF USE THEREOFJuly 2022May 2024Allow2230YesNo
17790079MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPYJune 2022September 2025Allow3900YesNo
17851454LANTHANIDE COMPLEX FORMULATIONSJune 2022April 2024Allow2220YesNo
17838638METHOD FOR REMOVING ACETALDEHYDEJune 2022January 2024Allow1920YesNo
17784215CGRP ANTIGONISTS USEFUL AS TRACER COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHYJune 2022April 2025Allow3400NoNo
17834773RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOFJune 2022May 2023Allow1110YesNo
17774529CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOFMay 2022July 2025Allow3901YesNo
17773282DIRECT FLUORESCENT GLYCAN LABELINGApril 2022October 2025Abandon4201NoNo
17755429SODIUM-DEPENDENT GLUCOSE TRANSPORTER 2 AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR PRE-MALIGNANT LESIONSApril 2022October 2025Abandon4210NoNo
17725237DRUG COMBINATION TREATMENTS USING BONE-TARGETING THERAPEUTICS FOR BONE AND BONE-RELATED DISEASEApril 2022October 2025Abandon4201NoNo
17722491AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORSApril 2022August 2025Allow4001YesNo
17701021SOLVENT FREE GADOLINIUM CONTRAST AGENTSMarch 2022July 2023Abandon1610NoNo
17699457CROSSLINKABLE POLYMER COMPOSITIONSMarch 2022May 2023Allow1410YesNo
17697369DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOFMarch 2022July 2023Abandon1610NoNo
17640259MANGANESE CHELATE ISOMERSMarch 2022March 2026Abandon4911NoNo
17638755PHOTOSENSITIZER-CONJUGATED ANTIMICROBIAL CELLULOSE NANOCRYSTALS AND METHODS OF SYNTHESIZING AND USING SAMEFebruary 2022March 2024Abandon2511NoNo
17674512NOOTROPIC FULLERENES AND USEFebruary 2022September 2025Abandon4301NoNo
17671128PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOFFebruary 2022July 2023Allow1710NoNo
17587595TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULESJanuary 2022September 2025Allow4340NoNo
17585118STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONSJanuary 2022February 2026Allow4961YesNo
17581465FULLERENE GABA DOPA AND METHODSJanuary 2022April 2024Abandon2711NoNo
17579967C60 GLUTATHIONE DOPA AND METHODSJanuary 2022October 2025Abandon4501NoNo
17535168BIOCOMPATIBLE MAGNETIC MATERIALSNovember 2021December 2024Allow3721YesYes
17604590NANO-ANTIBIOTICS BASED ON SINGLE-CHAIN DEXTRAN NANOPARTICLESOctober 2021August 2024Abandon3421NoNo
17501608ATHEROSCLEROSIS IMAGING AGENTS AND METHODS OF USING THE SAMEOctober 2021November 2025Abandon4920NoYes
17594193LOCALIZATION OF PAYLOAD DELIVERY SYSTEMS TO TUMOR SITES VIA BEACON CELL TARGETINGOctober 2021October 2024Allow3621NoNo
17476852PYRIMIDINE NUCLEOSIDE COMPOUNDS FOR FLUORESCENCE IMAGING AND SPECTROSCOPYSeptember 2021February 2025Allow4100NoNo
17440129COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULESSeptember 2021November 2025Allow5011YesNo
17437678DOSAGE FORM COMPRISING A POLYMERIC MATRIXSeptember 2021November 2022Allow1520YesNo
17470643COMPLEXSeptember 2021April 2024Allow3120NoNo
17437579HYDROGELS AND METHODS OF USING THE SAMESeptember 2021January 2024Allow2811YesNo
17434450COMPOSITION AND COMPOSITEAugust 2021May 2025Abandon4501NoNo
17434445POLARIZATION SOURCE FOR DYNAMIC NUCLEAR POLARIZATION, COMPOSITION, COMPOSITION FOR DYNAMIC NUCLEAR POLARIZATION, METHOD FOR HYPERPOLARIZATION, HYPERPOLARIZED SUBSTANCE AND NMR MEASUREMENT METHODAugust 2021June 2025Abandon4601NoNo
17433252In Vitro Assays as Indicator of Local ToleranceAugust 2021January 2025Abandon4110NoNo
17408972NANOPARTICLES FOR CANCER DETECTIONAugust 2021April 2024Abandon3220YesNo
17431396PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED TISSUE SPECIFICITYAugust 2021January 2026Abandon5321YesNo
17393837NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALSAugust 2021November 2023Allow2711YesNo
17385735RADIOPAQUE MONOMERS, POLYMERS, MICROSPHERES, AND METHODS RELATED THERETOJuly 2021August 2023Allow2420NoNo
17425857DELIVERY OF MACROMOLECULES INTO THE CENTRAL NERVOUS SYSTEM VIA THE BLOODSTREAMJuly 2021December 2025Abandon5221NoYes
17368574PHOTODYNAMIC THERAPY COMPOSITIONJuly 2021September 2025Allow5050YesYes
17357345COMPOSITE MEDICAL TEXTILE WITH NON-RESORBABLE FIBERS AND BIORESORBABLE HYALURONAN-BASED FIBERSJune 2021March 2024Abandon3250YesNo
17416180SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASEJune 2021May 2025Abandon4701NoNo
17415649DUAL MODE 18F-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOFJune 2021May 2025Allow4611NoNo
17414508PHARMACEUTICAL COMPOSITIONS COMPRISING GD-COMPLEXES AND POLYARYLENE ADDITIVESJune 2021December 2024Allow4250NoNo
17348157THERMOGELLING SUPRAMOLECULAR SPONGE AS SELF-HEALING AND BIOCOMPATIBLE HYDROGELJune 2021June 2024Allow3620YesYes
17339843TOPICAL GLYCOPYRROLATE FORMULATIONSJune 2021May 2023Abandon2310NoNo
17329891RADIOPAQUE POLYMERSMay 2021December 2023Allow3120NoYes
17309345SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALSMay 2021May 2025Abandon4820NoNo
17295647FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOFMay 2021January 2024Allow3220YesNo
17313424Hemocompatibility Modifiers For Cross-Linked Polymeric MaterialMay 2021December 2023Abandon3120NoNo
17290605CROSS-LINKED SUPRAMOLECULAR NANOPARTICLES FOR CONTROLLED RELEASE OF ANTIFUNGAL DRUGS AND STEROIDS - A NEW THERAPEUTIC APPROACH FOR ONYCHOMYCOSIS AND KELOIDApril 2021April 2024Abandon3511NoNo
17238473Crosslinked Gels Comprising Polyalkyleneimines, And Their Uses As Medical DevicesApril 2021July 2023Allow2720NoNo
17286123CHEMILUMINESCENT AND FLUORESCENT NANOPARTICLE FOR OPTICAL IMAGING OF CANCERApril 2021December 2025Allow5621YesNo
17226028VACCINES AND VACCINE COMPONENTS FOR INHIBITION OF MICROBIAL CELLSApril 2021November 2023Allow3100NoNo
17283412BIO-INSPIRED DEGRADABLE TOUGH ADHESIVES FOR DIVERSE WET SURFACESApril 2021December 2025Abandon5651YesNo
17214118COATED BODY AND COATING COMPOSITIONMarch 2021June 2024Abandon3910NoNo
17280760DEGRADABLE HYALURONIC ACID HYDROGELSMarch 2021December 2025Allow5651YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROGERS, JAMES WILLIAM.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
42
Examiner Affirmed
28
(66.7%)
Examiner Reversed
14
(33.3%)
Reversal Percentile
49.1%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
191
Allowed After Appeal Filing
44
(23.0%)
Not Allowed After Appeal Filing
147
(77.0%)
Filing Benefit Percentile
30.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ROGERS, JAMES WILLIAM - Prosecution Strategy Guide

Executive Summary

Examiner ROGERS, JAMES WILLIAM works in Art Unit 1618 and has examined 1,048 patent applications in our dataset. With an allowance rate of 45.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner ROGERS, JAMES WILLIAM's allowance rate of 45.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ROGERS, JAMES WILLIAM receive 2.55 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROGERS, JAMES WILLIAM is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +17.4% benefit to allowance rate for applications examined by ROGERS, JAMES WILLIAM. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.3% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.2% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 74.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 65.9% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.0% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.9% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 54% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.